Why the study?
Cardiac amyloidosis can cause aggressive heart failure, and while cardiac contractility modulation is an established therapy for symptomatic heart failure, evidence for its use in cardiac amyloidosis is lacking.
Does cardiac contractility modulation therapy improve clinical status and functional capacity in patients with TTR amyloid cardiomyopathy and heart failure?
Does cardiac contractility modulation therapy improve clinical status and functional capacity in patients with TTR amyloid cardiomyopathy and heart failure?
Cardiac contractility modulation therapy may be an effective therapeutic option for improving functional status and reducing hospitalizations in patients with TTR amyloid cardiomyopathy and severe heart failure.
Hypothesis-generating for cardiac contractility modulation in TTR amyloid cardiomyopathy; prospective trials needed before practice change.
Cardiac amyloidosis may result in an aggressive form of heart failure (HF). Cardiac contractility modulation (CCM) has been shown to be a concrete therapeutic option in patients with symptomatic HF, but there is no evidence of its application in patients with cardiac amyloidosis. We present the case of TTR amyloidosis, where CCM therapy proved to be effective. The patient had a history of multiple HF hospitalizations due to an established diagnosis of wild type TTR-Amyloidosis with significant cardiac involvement. Since he was highly symptomatic, except during continuous dobutamine and diuretic infusion, it was opted to pursue CCM therapy device implantation. At follow up, a significant improvement in clinical status was reported with an increase of EF, functional status (6 min walk test improved from zero meters at baseline, to 270 m at 1 month and to 460 m at 12 months), and a reduction in pulmonary pressures. One year after device implantation, no other HF hospital admission was needed. CCM therapy may be effective in this difficult clinical setting. The AMY-CCM Registry, which has just begun, will evaluate the efficacy of CCM in patients with HF and diagnosed TTR amyloidosis to bring new evidence on its potential impact as a therapeutic option.
No takes yet. Share an insight, caveat, or question.
Marchese et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: